NASDAQ:RNA Avidity Biosciences (RNA) Stock Price, News & Analysis $44.48 -1.17 (-2.56%) (As of 09/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends Get Avidity Biosciences alerts: Email Address About Avidity Biosciences Stock (NASDAQ:RNA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Avidity Biosciences alerts:Sign Up Key Stats Today's Range$44.05▼$46.0950-Day Range$40.46▼$48.1452-Week Range$4.82▼$48.80Volume5.00 million shsAverage Volume1.36 million shsMarket Capitalization$4.25 billionP/E RatioN/ADividend YieldN/APrice Target$61.00Consensus RatingBuy Company OverviewAvidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Read More… Is Starlink Set For The Largest IPO In History? (Ad)He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!Click here now for the urgent details. Avidity Biosciences Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 63rd PercentileAvidity Biosciences scored higher than 63% of companies evaluated by MarketBeat, and ranked 394th out of 1,003 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingAvidity Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAvidity Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Avidity Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Avidity Biosciences are expected to decrease in the coming year, from ($3.01) to ($3.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avidity Biosciences is -15.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avidity Biosciences is -15.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvidity Biosciences has a P/B Ratio of 6.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Avidity Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.30% of the outstanding shares of Avidity Biosciences have been sold short.Short Interest Ratio / Days to CoverAvidity Biosciences has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Avidity Biosciences has recently decreased by 16.33%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvidity Biosciences does not currently pay a dividend.Dividend GrowthAvidity Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.30% of the outstanding shares of Avidity Biosciences have been sold short.Short Interest Ratio / Days to CoverAvidity Biosciences has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Avidity Biosciences has recently decreased by 16.33%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.48 News SentimentAvidity Biosciences has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Avidity Biosciences this week, compared to 4 articles on an average week.Search Interest10 people have searched for RNA on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Avidity Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Avidity Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,011,490.00 in company stock.Percentage Held by InsidersOnly 3.68% of the stock of Avidity Biosciences is held by insiders.Read more about Avidity Biosciences' insider trading history. Receive RNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RNA Stock News HeadlinesAvidity Biosciences, Inc. (NASDAQ:RNA) Director Arthur A. Levin Sells 5,000 SharesSeptember 21 at 9:27 AM | insidertrades.comAvidity Biosciences (NASDAQ:RNA) Trading Up 4.1%September 20 at 7:46 AM | americanbankingnews.comWho are Nvidia’s New Silent Partners?Nvidia knows it can’t stand still as AI continues to grow at an exponential rate. That’s why CEO Jensen Huang consistently has his company ahead of the curve when it comes to artificial intelligence. Nvidia’s added $2 trillion in market cap in 2024.September 21, 2024 | Weiss Ratings (Ad)Cantor Fitzgerald Reaffirms Their Buy Rating on Avidity Biosciences (RNA)September 19 at 5:50 AM | markets.businessinsider.comAvidity Biosciences (NASDAQ:RNA) Given "Overweight" Rating at Cantor FitzgeraldSeptember 17, 2024 | americanbankingnews.comUnveiling 7 Analyst Insights On Avidity BiosciencesSeptember 16, 2024 | benzinga.comAvidity Biosciences executive sells over $4.5 million in company stockSeptember 15, 2024 | uk.investing.comAvidity Biosciences: Strong Buy on Promising Clinical Data and Reduced CompetitionSeptember 14, 2024 | markets.businessinsider.comSee More Headlines RNA Stock Analysis - Frequently Asked Questions How have RNA shares performed this year? Avidity Biosciences' stock was trading at $9.05 on January 1st, 2024. Since then, RNA shares have increased by 391.5% and is now trading at $44.48. View the best growth stocks for 2024 here. How were Avidity Biosciences' earnings last quarter? Avidity Biosciences, Inc. (NASDAQ:RNA) posted its earnings results on Friday, August, 9th. The biotechnology company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.11. The biotechnology company earned $2.05 million during the quarter, compared to analyst estimates of $7.09 million. Avidity Biosciences had a negative trailing twelve-month return on equity of 32.89% and a negative net margin of 2,381.82%. When did Avidity Biosciences IPO? Avidity Biosciences (RNA) raised $150 million in an initial public offering on Friday, June 12th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO. Who are Avidity Biosciences' major shareholders? Avidity Biosciences' top institutional shareholders include Avoro Capital Advisors LLC (6.80%), Cowen AND Company LLC (5.36%), D. E. Shaw & Co. Inc. (0.77%) and Dimensional Fund Advisors LP (0.72%). Insiders that own company stock include Sarah Boyce, Michael F Maclean, W Michael Flanagan and Arthur A Levin. View institutional ownership trends. How do I buy shares of Avidity Biosciences? Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Avidity Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX) and iBio (IBIO). Company Calendar Last Earnings8/09/2024Today9/21/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RNA CUSIPN/A CIK1574111 Webwww.aviditybiosciences.com Phone858-401-7900FaxN/AEmployees190Year FoundedN/APrice Target and Rating Average Stock Price Target$61.00 High Stock Price Target$96.00 Low Stock Price Target$45.00 Potential Upside/Downside+37.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-212,220,000.00 Net Margins-2,381.82% Pretax Margin-2,381.82% Return on Equity-32.89% Return on Assets-28.85% Debt Debt-to-Equity RatioN/A Current Ratio15.78 Quick Ratio15.78 Sales & Book Value Annual Sales$9.56 million Price / Sales510.87 Cash FlowN/A Price / Cash FlowN/A Book Value$6.76 per share Price / Book6.58Miscellaneous Outstanding Shares109,800,000Free Float92,118,000Market Cap$4.88 billion OptionableOptionable Beta0.89 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:RNA) was last updated on 9/21/2024 by MarketBeat.com Staff From Our PartnersThe Perfect Storm for an EV RevoltNot many people realize there’s a "perfect storm" for profits unfolding in the auto industry - today. Globa...Eagle Publishing | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.